Literature DB >> 2942252

Abnormalities of T cells isolated from mediastinal lymph nodes and peripheral blood of patients with lung carcinoma: deficit in PHA-induced expression of HLA class II antigens and in autologous mixed lymphocyte reactions.

F Indiveri, I Pierri, S Rogna, A Poggi, R Romano, A Tavano, G Ratto, G Motta, S Ferrone.   

Abstract

A reduced percentage of T cells isolated from mediastinal lymph nodes and peripheral blood of patients with lung carcinoma acquired HLA Class II antigens following in vitro stimulation with PHA. Furthermore T cells were functionally abnormal in autologous and allogeneic mixed lymphocyte reactions (MLR). The immunoregulatory properties of HLA Class II antigens and autologous MLRs suggest that these abnormalities may affect the interaction of the host's immune system with tumor cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942252     DOI: 10.1007/bf00200038

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

1.  T cells from patients with chronic liver diseases: abnormalities in PHA-induced expression of HLA class II antigens and in autologous mixed-lymphocyte reactions.

Authors:  M Scudeletti; F Indiveri; I Pierri; A Picciotto; S Ferrone
Journal:  Cell Immunol       Date:  1986-10-01       Impact factor: 4.868

2.  Purification of immunologically functional subsets of human Ia-like antigens on a monoclonal antibody (Q5/13) immunoadsorbent.

Authors:  V Quaranta; L E Walker; M A Pellegrino; S Ferrone
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

Review 3.  The autologous mixed-lymphocyte reaction.

Authors:  M E Weksler; C E Moody; R W Kozak
Journal:  Adv Immunol       Date:  1981       Impact factor: 3.543

4.  Lymphocyte transformation induced by autologous cells. XI. The effect of age on the autologous mixed lymphocyte reaction.

Authors:  C E Moody; J B Innes; L Staiano-Coico; G S Incefy; H T Thaler; M E Weksler
Journal:  Immunology       Date:  1981-10       Impact factor: 7.397

5.  Detection of human histocompatibility (HLA) antigens with an indirect rosette microassay.

Authors:  F Indiveri; B S Wilson; M A Pellegrino; S Ferrone
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

6.  Isolation of human T and B lymphocytes by rosette formation with 2-aminoethylisothiquronium bromide (AET) -treated sheep red blood cells with monkey red blood cells.

Authors:  M A Pellegrino; S Ferrone; A N Theofilopoulos
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

7.  The free and the beta 2-microglobulin-associated heavy chains of HLA-A, B alloantigens share the antigenic determinant recognized by the monoclonal antibody Q1/28.

Authors:  V Quaranta; L E Walker; G Ruberto; M A Pellegrino; S Ferrone
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

8.  Immunoregulatory properties of human esophageal tumor extract.

Authors:  N Mohagheghpour; B Parhami; K Dowlatshahi; D Kadjehnouri; J H Elder; F V Chisari
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

9.  Human T lymphocytes in aging and malignancy: abnormalities in PHA-induced Ia antigen expression and in functional activity in autologous and allogeneic MLR.

Authors:  F Indiveri; I Pierri; D Viglione; D Pende; C Russo; M A Pellegrino; S Ferrone
Journal:  Cell Immunol       Date:  1983-03       Impact factor: 4.868

10.  Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1.

Authors:  B Perussia; S Starr; S Abraham; V Fanning; G Trinchieri
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

View more
  1 in total

1.  CD4+ Th0 cell clones, isolated from a metastatic lymph node of a melanoma patient, possess cytolytic function.

Authors:  M A Imro; C Castagneto; O Bosco; P Modena; L Lanza; F Puppo; G Filaci; F Indiveri; M Scudeletti
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.